#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that the market proliferation of high-THC cannabis products far exceeds the clinical evidence base supporting their safety and efficacy, creating a gap between what patients can purchase and what research actually supports for treatment decisions. This evidence shortage means clinicians lack robust data on dosing, adverse effects, and long-term outcomes for the potent products their patients are increasingly using, limiting their ability to provide informed counseling and monitoring. Without adequate research on high-THC formulations, clinicians cannot reliably assess individual patient risk-benefit profiles or recommend evidence-based alternatives.
A systematic review of nearly 10,000 published studies on cannabis identified only 15 that met rigorous evidence criteria, revealing a substantial gap between the proliferation of high-THC products on the market and the clinical evidence supporting their safety and efficacy. The researchers from Monash Addiction Research Centre found that despite widespread commercial availability and increasing potency of cannabis products, the scientific literature remains sparse and limited in demonstrating clear therapeutic benefits or establishing safe dosing guidelines for high-THC formulations. This evidence gap is particularly concerning given that high-THC products are increasingly dominant in legal cannabis markets, yet their clinical role and risk profile remain poorly characterized compared to traditional cannabis preparations or other cannabinoid formulations. Clinicians lack robust data to counsel patients on appropriate indications, dosing, drug interactions, or long-term safety profiles for these potent products, which limits evidence-based prescribing and informed consent. The mismatch between market availability and clinical evidence underscores the need for rigorous clinical trials to establish whether high-THC products offer therapeutic advantages over alternative treatments. Clinicians should inform patients that many cannabis products available today, particularly high-potency options, lack adequate clinical evidence of safety and efficacy, and encourage shared decision-making based on the limited evidence currently available.
“What we’re seeing is a significant gap between the market velocity of high-THC products and our actual understanding of their safety and efficacy profiles in diverse populations, which is concerning from a clinical standpoint. The evidence base we have is simply too thin to guide confident prescribing or patient counseling for these increasingly potent formulations.”
🧠 The rapid proliferation of high-THC cannabis products in legal markets has substantially outpaced the clinical evidence base needed to guide patient care and risk counseling. A recent systematic review identifying only 15 eligible studies from nearly 10,000 publications underscores significant gaps in our understanding of how potency affects therapeutic outcomes, adverse effects, and long-term safety across diverse populations. This evidence-practice gap is complicated by variability in study design, product composition, dosing protocols, and patient demographics, making it difficult to synthesize generalizable recommendations for different clinical contexts. Clinicians should be aware that patients presenting with cannabis use are increasingly likely to be consuming products with THC concentrations substantially higher than historical averages, yet our ability to predict individual vulnerability to harms remains limited. In clinical practice, this means taking a more granular history of product type and potency, maintaining heightened vigilance for cannabinoid hyperemesis syndrome
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
